Nabriva

NBRV NASDAQ
2.070
+0.020
+0.98%
Closed 18:39 08/22 EDT
Open
2.020
Prev Close
2.050
High
2.090
Low
1.920
Volume
2.71M
Avg Vol (3M)
1.12M
52 Week High
3.270
52 Week Low
1.120
% Turnover
3.69%
Market Cap
151.86M
1D
5D
1M
3M
1Y
5Y

Related

Webull offers Nabriva NBRV stock price, real time market quotes, professional analyst ratings, and in-depth charts, You can share investing ideas in community to communicate with others and learn trading skills.

Company Profile

Nabriva Therapeutics plc is a clinical stage biopharmaceutical company. The Company is engaged in engaged in the research and development of novel anti-infectives to treat serious infections, with a focus on the pleuromutilin class of antibiotics. The Company’s medicinal chemistry has enabled targeted discovery of novel pleuromutilins, including both intravenous and oral formulations of its lead product candidate, lefamulin. Lefamulin is a novel semi-synthetic pleuromutilin antibiotic with the potential to be the first-in-class available for systemic administration in humans. Lefamulin is being evaluated in two global, registrational Phase III clinical trials in patients with moderate to severe community-acquired bacterial pneumonia (CABP).It seeks to further pursue development of lefamulin for additional indications, including the treatment of acute bacterial skin and skin structure infections (ABSSSI), and is developing a formulation of lefamulin appropriate for pediatric use.
MORE >

Recently

Name
Price
%Change